Objective: To study expressions of matrix metalloproteinase-13 (PCNA) in triple negative (ER-, PR-, HER2-) breast cancers and evaluate their clinical significance.

Methods: The immunohistochemistry SP method was used to evaluate the expressions of PCNA in 32 cases of triple negative breast cancers, 24 cases of HR breast cancer (ER+/PR+, HER-2-), 12 cases of HER2 breast cancer (ER-, PR-, HER2+) and 12 cases of breast fibroadenoma and their correlations to clinicopathologic features were analyzed.

Results: The expressions of PCNA were significantly higher in the triple negative breast cancers than in breast fibroadenoma and HR breast cancers (P<0.05). Furthermore, the expression of PCNA was significantly higher in the triple negative breast cancers than in HER2 breast cancers (P <0.05). In the triple negative breast cancers, PCNA expression was associated with axillary lymph node metastasis and TNM stage (P <0.05), but it was not correlated with patients age (P >0.05). Correlation analysis showed that PCNA expression was positively correlated in the triple negative breast can cers, HR breast cancers and HER2 breast cancers (P <0.05).

Conclusion: There is a close relationship between PCNA the occurrence and development of triple negative breast cancers, and PCNA could serve as important indexes in the aspect of invasiveness and metastasis in triple negative breast cancers.

Citation Format: Peng Jiaping, meng qun. Expressions of PCNA in triple-negative breast cancers and their clinical significance. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B104.